Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | KDM5A | P29375 | 3/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 9/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15782634 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRKDM5APAOX | |
| SCHEMBL2055302 | 0.92 | KMT2A (0.58) | MEN1KMT2ATSHRKDM5AALDH1A1 | |
| SCHEMBL2055301 | 0.92 | KMT2A (0.58) | MEN1KMT2ATSHRKDM5AALDH1A1 | |
| SCHEMBL2055296 | 0.92 | KMT2A (0.58) | MEN1KMT2ATSHRKDM5AALDH1A1 | |
| SCHEMBL15782646 | 0.91 | MEN1 (0.47) | MEN1KMT2ATSHRKDM5APAOX | |
| SCHEMBL2055298 | 0.90 | KMT2A (0.56) | MEN1KMT2ATSHRKDM5AALDH1A1 | |
| SCHEMBL2055297 | 0.90 | KMT2A (0.56) | MEN1KMT2ATSHRKDM5AALDH1A1 | |
| SCHEMBL15782643 | 0.89 | PAOX (0.53) | MEN1KMT2ATSHRKDM5APAOX | |
| SCHEMBL15782645 | 0.88 | PAOX (0.49) | MEN1KMT2ATSHRKDM5APAOX | |
| SCHEMBL15781643 | 0.88 | KMT2A (0.67) | MEN1KMT2ATSHRKDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | MEN1 718/4885KMT2A 2906/4885TSHR 2608/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | MEN1 1363/4885KMT2A 2031/4885TSHR 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.